演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

BBP不応切除不能大腸癌におけるFOLFIRI plus ramucirumab or afribercept療法の有効性

演題番号 : P19-1

[筆頭演者]
演者)吉田 啓紀:1 
[共同演者]
安藤 孝将:1、島田 清太郎:1、作村 美穂:1、高嶋 祐介:1、南條 宗八:1、三原 弘:1、梶浦 新也:1、藤浪 斗:1、小林 由夏:3、安田 一朗:1、杉山 敏郎:2

1:富山大学・第3内科、2:富山大学・地域がん予防・治療学推進講座、3:長岡中央綜合病院・腫瘍内科

 

Background:
The switching to aflibercept has been reported to inhibit tumor growth with bevacizumab resistance in rodent models. Therefore, the aim of this study is to evaluate the efficacy and safety of FOLFIRI plus afribercept or ramucirumab in patients with bevacizumab beyond PD (BBP) refractory metastatic colorectal cancer (mCRC).
Methods:
We retrospectively analyzed the medical records of eight patients with BBP refractory mCRC who received FOLFIRI plus afribercept or ramucirumab. The treatment efficacy was evaluated by response rate (RR), disease control rate (DCR), and progression free survival (PFS). The safety was analyzed by adverse events (AEs) of CTCAE ver. 4.0.
Results:
Patients characteristics were as follows; male/female 3/5, median age 69 (range 57-80), ECOG PS (0/1/2) 2/5/1, RAS wild/mutant 5/3, median prior regimens 3 (range 2-5), angiogenesis inhibitor afribercept/ramucirumab 2/6. In analysis of efficacy, RR and DCR were 13% (1/8) and 63% (5/8), respectively. Median PFS was 5.6 months and median OS was not reached. The common ≧grade 3 AEs was only neutrophil decreased (63%, 5/8).
Conclusions:
FOLFIRI plus afribercept or ramucirumab showed moderate efficacy and manageable safety profile in patients with BBP refractory mCRC. This treatment may be therapeutic option even in patients with mCRC refractory or intolerant to standard therapies.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る